Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1251 to 1300 of 1867 results for do not do

  1. Reducing the risk of transmission of Creutzfeldt–Jakob disease (CJD) from surgical instruments used for interventional procedures on high-risk tissues (HTG535)

    Evidence-based recommendations on reducing the risk of transmission of Creutzfeldt–Jakob disease (CJD) from surgical instruments used for interventional procedures on high-risk tissues. These procedures on high-risk tissues are intradural surgery on the brain (including the pituitary gland) and spinal cord, neuroendoscopy, and surgery on the retina or optic nerve.

    HealthTech guidance
    Published
    22 January 2020
    View recommendations

    Sections for HTG535

  2. The evidence on the safety of transurethral laser ablation for recurrent non-muscle-invasive bladder cancer shows that there are no major safety concerns. However, current evidence on its efficacy is limited in quality and quantity. Therefore, this procedure should only be used with  special arrangements   for clinical governance, consent, and audit or research.

    research. Any explanatory notes(if applicable) Clinicians wishing to do transurethral laser ablation for recurrent non-muscle-invasive...

    Research recommendation
    Published
    15 November 2019

  3. Use of hearing aids and incidence of dementia:- In adults with hearing loss, does the use of hearing aids reduce the incidence of dementia?

    hearing aids delay the onset or reduce the incidence of dementia. Hearing aids do, however, have the potential to improve functioning...

    Research recommendation
    Published
    10 December 2018

  4. Factors predicting outcomes for people with high-grade transformation of follicular lymphoma:- In people with high-grade transformation of follicular lymphoma, which biological and clinical factors predict good outcomes with immunochemotherapy alone?

    clinical event, outcomes have improved. It is unclear which people are likely to do well with conventional treatment (such as R-CHOP)...

    Research recommendation
    Published
    25 August 2016

  5. Spectra Optia for automatic red blood cell exchange in people with sickle cell disease (HTG405)

    Evidence-based recommendations on Spectra Optia for automated red blood cell exchange in people with sickle cell disease.

    HealthTech guidance
    Published
    2 March 2016
    View recommendations

    Sections for HTG405

  6. Guide to the technology appraisal and highly specialised technologies appeal process (pre June 2023) (PMG18)

    This document concerns the appeal process for the technology appraisal and highly specialised technologies programmes and provides an overview for organisations wishing to lodge an appeal

  7. Coeliac disease (QS134)

    This quality standard covers recognising, assessing and managing coeliac disease in adults, young people and children. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    19 October 2016
    View quality statements

    Sections for QS134

  8. Neonatal parenteral nutrition (QS205)

    This quality standard covers parenteral nutrition (intravenous feeding) for babies born preterm, up to 28 days after their due birth date, and babies born at term, up to 28 days after their birth. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    22 March 2022
    View quality statements

    Sections for QS205

  9. Healthy workplaces: improving employee mental and physical health and wellbeing (QS147)

    This quality standard covers the health and wellbeing of all employees, including their mental health. It describes high-quality care in priority areas for improvement. It does not cover managing long-term sickness absence.

    Quality standard
    Published
    3 March 2017
    View quality statements

    Sections for QS147

  10. Transition between inpatient mental health settings and community or care home settings (QS159)

    This quality standard covers transitions for children, young people and adults between mental health hospitals and their own homes, care homes or other community settings. It includes the period before, during and after a person is admitted to, and discharged from, a mental health hospital. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    12 September 2017
    View quality statements

    Sections for QS159

  11. The Insides System for managing intestinal failure (MIB286)

    NICE has developed a medtech innovation briefing (MIB) on The Insides System for managing intestinal failure .

    Medtech innovation briefing
    Published
    17 February 2022

  12. Simple home test prevents thousands of unnecessary bowel cancer referrals

    A simple home test is sparing thousands of people from unnecessary hospital investigations for bowel cancer, while helping them get faster answers about whether they have the disease – with new data showing the impact of NICE's recommendation to use the test.

    News
    Last updated
    6 February 2026

  13. MiniMed 640G system with SmartGuard for managing blood glucose levels in people with type 1 diabetes (MIB51)

    NICE has developed a medtech innovation briefing (MIB) on MiniMed 640G system with SmartGuard for managing blood glucose levels in people with type 1 diabetes

    Medtech innovation briefing
    Published
    12 February 2016

  14. What is the efficacy and safety of remdesivir for people who have been vaccinated against COVID-19?

    (Population, Intervention, Comparator, Outcomes) P: people with COVID-19 who do not need supplemental oxygen and are within 7 days of...

    Research recommendation
    Published
    9 March 2022

  15. Risk assessment:- What is the accuracy of individual risk assessment tools in predicting the risk of venousthromboembolism (VTE) and risk of bleeding in people admitted to hospital?

    means that the national tool identifies too many people or the other tools do not identify enough. The potential impact of giving...

    Research recommendation
    Published
    15 November 2018

  16. What is the effectiveness of awake body positioning in improving outcomes for people in hospital with COVID-19 who are not intubated and have higher oxygen needs?

    mean duration of body positioning• people on general wards, and those with do-not-intubate goals of care• supplemental oxygen type•...

    Research recommendation
    Published
    9 March 2022

  17. What is the clinical and cost effectiveness of enhanced recovery programmes for adults having major emergency surgery?

    hospitals. To implement this recommendation, specialties and hospitals that do not currently provide an ERP covering all 3 stages of...

    Research recommendation
    Published
    26 October 2020

  18. The evidence on the safety of reinforcement of a permanent stoma with a synthetic or biological mesh to prevent a parastomal hernia shows there are serious but well-recognised complications. The evidence on efficacy is limited in quantity and quality. Therefore, this procedure should not be used unless  special arrangements   are in place for clinical governance, consent, and audit or research.

    research. Any explanatory notes(if applicable) Clinicians wishing to do reinforcement of a permanent stoma with a synthetic or...

    Research recommendation
    Published
    15 November 2019

  19. Education and training programmes: self-management:- What is the effectiveness and cost effectiveness of education programmes to improve information and advice and to support self-management of chronic health conditions (for example, obesity, diabetes and cardiovascular disease) for people growing older with learning disabilities, and their family members and carers?

    disabilities are more likely to have missed appointments with health professionals, do not have optimal medication management and have...

    Research recommendation
    Published
    29 November 2018

  20. Extended access to GP services:- Is extended access to GP services, for example during early mornings, evenings and weekends, more clinically and cost effective than standard access?

    in operation for general practice are for prebooked appointments only and do not provide emergency care. The focus of this research...

    Research recommendation
    Published
    15 November 2018

  21. The evidence on percutaneous insertion of a cerebral protection device to prevent cerebral embolism during TAVI raises no major safety concerns other than those associated with the TAVI procedure. However, the evidence on efficacy for preventing TAVI-related stroke is inconclusive. Therefore, this procedure should only be used with  special arrangements   for clinical governance, consent, and audit or research.

    research. Any explanatory notes(if applicable) Clinicians wishing to do percutaneous insertion of a cerebral protection device to...

    Research recommendation
    Published
    15 November 2019

  22. PredictSURE IBD and IBDX to guide treatment of Crohn's disease (HTG610)

    Evidence-based recommendations on PredictSURE IBD and IBDX for guiding treatment of Crohn’s disease.

    HealthTech guidance
    Published
    23 February 2022
    View recommendations

    Sections for HTG610

  23. Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy for treating morbid obesity (HTG423)

    Evidence-based recommendations on single-anastomosis duodeno-ileal bypass with sleeve gastrectomy for treating morbid obesity. This involves reducing the size of the stomach and small intestine to reduce the amount of food absorbed.

    HealthTech guidance
    Published
    23 November 2016
    View recommendations

    Sections for HTG423

  24. Ultrasound‑enhanced, catheter‑directed thrombolysis for pulmonary embolism (HTG376)

    Evidence-based recommendations on ultrasound enhanced catheter-directed thrombolysis for pulmonary embolism. This involves using ultrasound waves and a drug to break up the clot.

    HealthTech guidance
    Published
    26 June 2015
    View recommendations

    Sections for HTG376

  25. superDimension Navigation System to help diagnostic sampling of peripheral lung lesions (MIB194)

    NICE has developed a medtech innovation briefing (MIB) on superDimension Navigation System to help diagnostic sampling of peripheral lung lesions .

    Medtech innovation briefing
    Published
    11 October 2019

  26. Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders (TA748)

    Evidence-based recommendations on mexiletine (Namuscla) for treating the symptoms of myotonia in adults with non-dystrophic myotonic disorders.

    Technology appraisal guidance
    Published
    1 December 2021
    View recommendations

    Sections for TA748

  27. Galcanezumab for preventing migraine (TA659)

    Evidence-based recommendations on galcanezumab (Emgality) for preventing migraine in adults.

    Technology appraisal guidance
    Published
    18 November 2020
    View recommendations

    Sections for TA659

  28. Cabozantinib for treating medullary thyroid cancer (TA516)

    Evidence-based recommendations on cabozantinib (Cometriq) for treating medullary thyroid cancer in adults.

    Technology appraisal guidance
    Published
    28 March 2018
    View recommendations

    Sections for TA516

  29. Renal and ureteric stones (QS195)

    This quality standard covers assessing and managing renal and ureteric stones in children, young people and adults. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    29 July 2020
    View quality statements

    Sections for QS195

  30. Learning disability: identifying and managing mental health problems (QS142)

    This quality standard covers the prevention, assessment and management of mental health problems in people with learning disabilities in all settings (including health, social care, education, and forensic and criminal justice). It also covers family members, carers and care workers.

    Quality standard
    Published
    10 January 2017
    View quality statements

    Sections for QS142

  31. Spinal metastases and metastatic spinal cord compression (QS56)

    This quality standard covers diagnosis and management of spinal metastases and metastatic spinal cord compression. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    6 September 2023
    View quality statements

    Sections for QS56

  32. Esketamine nasal spray for treatment-resistant depression (TA854)

    Evidence-based recommendations on esketamine (Spravato) for treatment-resistant depression in adults.

    Technology appraisal guidance
    Published
    14 December 2022
    View recommendations

    Sections for TA854

  33. Guide to the processes of technology appraisal (PMG19)

    This document is one of a series describing the processes and methods that NICE uses to carry out technology appraisals. It focuses on the technology appraisal processes

  34. Truncal treatment with or without concurrent tributary treatment:- What is the clinical and cost effectiveness of concurrent phlebectomies or foam sclerotherapy for varicose tributaries during truncal endothermal ablation for varicose veins compared with: - truncal endothermal ablation without concurrent phlebectomies or foam sclerotherapy? - truncal endothermal ablation with phlebectomies or foam sclerotherapy, if needed, 6–12 weeks later?

    tributary treatment may reduce morbidity, and also mean that some patients do not need tributary treatment (or need fewer tributary...

    Research recommendation
    Published
    9 June 2015

  35. What are the long-term outcomes, both psychotic and nonpsychotic, for children and young people with attenuated or transient psychotic symptoms suggestive of a developing psychosis, and can the criteria for 'at risk states' be refined to better predict those who will and those who will not go on to develop psychosis?

    most at risk, and reduce the numbers of those thought to be 'at risk' who do not go on to later develop psychosis. Source guidance...

    Research recommendation
    Published
    9 June 2015

  36. Next-generation sequencing panel for solid tumour cancers in children (MIB133)

    NICE has developed a medtech innovation briefing (MIB) on the next-generation sequencing panel for solid tumour cancers in children .

    Medtech innovation briefing
    Published
    8 January 2018

  37. Natural Cycles for monitoring fertility (MIB244)

    NICE has developed a medtech innovation briefing (MIB) on Natural Cycles for monitoring fertility .

    Medtech innovation briefing
    Published
    19 January 2021

  38. Aptiva for painful diabetic neuropathy (MIB119)

    NICE has developed a medtech innovation briefing (MIB) on Aptiva for painful diabetic neuropathy .

    Medtech innovation briefing
    Published
    13 September 2017

  39. SecurAcath for securing percutaneous catheters (HTG440)

    Evidence-based recommendations on SecurAcath for securing percutaneous catheters.

    HealthTech guidance
    Last updated
    10 August 2022
    View recommendations

    Sections for HTG440

  40. Devices for remote monitoring of Parkinson's disease (HTG657)

    Evidence-based recommendations on Kinesia 360 and KinesiaU (Great Lakes NeuroTechnologies), PDMonitor (PD Neurotechnology), Personal KinetiGraph (Global Kinetics) and STAT-ON (Sense4care) for remote monitoring of Parkinson’s disease.

    HealthTech guidance
    Last updated
    25 January 2024
    View recommendations

    Sections for HTG657

  41. Ultrasound‑enhanced, catheter‑directed thrombolysis for deep vein thrombosis (HTG375)

    Evidence-based recommendations on ultrasound enhanced catheter-directed thrombolysis for deep vein thrombosis. This involves using ultrasound waves and a drug to break up the clot.

    HealthTech guidance
    Published
    26 June 2015
    View recommendations

    Sections for HTG375

  42. Evidence on the safety and efficacy of prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia is limited in quantity and quality. Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. Find out what special arrangements mean on the NICE interventional procedures guidance page.

    page. Any explanatory notes(if applicable) Clinicians wanting to do prostatic urethral temporary implant insertion for lower urinary...

    Research recommendation
    Published
    30 September 2022

  43. Evidence on the efficacy and safety of neurostimulation of lumbar muscles for refractory non-specific chronic low back pain is limited in quantity and quality. Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. Find out what special arrangements mean on the NICE interventional procedures guidance page.

    page. Any explanatory notes(if applicable) Clinicians wanting to do neurostimulation of lumbar muscles for refractory non-specific...

    Research recommendation
    Published
    30 September 2022

  44. Effectiveness and cost effectiveness of drug misuse prevention interventions for groups vulnerable to drug misuse:- What is the effectiveness and cost effectiveness of drug misuse prevention interventions for groups vulnerable to drug misuse in the UK?

    festivals, would provide prevention data for hard-to-reach groups and those who do not access existing services. Research could also...

    Research recommendation
    Published
    4 May 2017

  45. Lead-I ECG devices for detecting symptomatic atrial fibrillation using single time point testing in primary care (HTG508)

    Evidence-based recommendations on lead-I electrocardiogram (ECG) devices (imPulse, Kardia Mobile, MyDiagnostick and Zenicor-ECG) for detecting symptomatic atrial fibrillation using single time point testing in primary care.

    HealthTech guidance
    Published
    8 May 2019
    View recommendations

    Sections for HTG508

  46. Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over (HST33)

    Evidence-based recommendations on leniolisib (Joenja) for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over.

    Highly specialised technologies guidance
    Published
    23 April 2025

    Sections for HST33

  47. ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot (MIB56)

    NICE has developed a medtech innovation briefing (MIB) on the ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot

    Medtech innovation briefing
    Published
    11 March 2016

  48. Aquilion PRIME CT scanner for imaging coronary artery disease in adults in whom imaging is difficult (MIB53)

    NICE has developed a medtech innovation briefing (MIB) on the Aquilion PRIME CT scanner for imaging coronary artery disease in adults in whom imaging is difficult .

    Medtech innovation briefing
    Last updated
    6 July 2017

  49. Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma (TA680)

    Evidence-based recommendations on lenalidomide (Revlimid) for maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma in adults.

    Technology appraisal guidance
    Published
    3 March 2021
    View recommendations

    Sections for TA680

  50. Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation (TA429)

    Evidence-based recommendations on ibrutinib (Imbruvica) for treating chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    25 January 2017
    View recommendations

    Sections for TA429